Sai Life Sciences, one of India's fastest growing global Contract Research, Development & Manufacturing Organisations (CRO-CDMO), has announced the opening of Sai Schrödinger Research Laboratories (SSRL) at its R&D campus in Hyderabad. The facility was inaugurated by Dr Karen Akinsanya, President of R&D, Therapeutics at Schrödinger Inc. (based in the US), in the presence of members of the leadership team of Schrödinger and Sai Life Sciences.

In January 2023, Sai Life Sciences entered into a 5-year strategic agreement with Schrödinger, whose physics-based computational platform is transforming the way therapeutics and materials are discovered, to set up SSRL in Hyderabad. Soon after, Sai Life Sciences commenced the build-up of the facility along with recruitment of scientific staff, to drive the project to completion in an accelerated time frame.

Set up inside Sai Life Sciences' R&D campus in Genome Valley, SSRL is a dedicated facility for integrated discovery work streams including medicinal & synthetic chemistry, in vitro biology, and process chemistry. SSRL will access other Sai capabilities such as in vitro ADME (Absorption, distribution, metabolism, and excretion) and in vivo PK (pharmacokinetics) as needed. The relationship will support advancement of programmes that leverage Schrödinger's validated computational platform. Currently, SSRL has 75 employees across full-time-equivalents (FTEs) in Medicinal Chemistry, Biology, Process Chemistry and Analytical Chemistry.